Sunesis Pharmaceuticals (NASDAQ: SNSS) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Sunesis Pharmaceuticals to related businesses based on the strength of its profitability, analyst recommendations, risk, earnings, institutional ownership, dividends and valuation.
This table compares Sunesis Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sunesis Pharmaceuticals Competitors||-3,323.02%||-533.68%||-40.13%|
This table compares Sunesis Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Sunesis Pharmaceuticals||$2.54 million||-$38.02 million||-1.25|
|Sunesis Pharmaceuticals Competitors||$217.29 million||-$39.39 million||-68.21|
Sunesis Pharmaceuticals’ peers have higher revenue, but lower earnings than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings and price targets for Sunesis Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sunesis Pharmaceuticals Competitors||533||2404||6583||123||2.65|
Sunesis Pharmaceuticals presently has a consensus price target of $4.00, indicating a potential upside of 83.49%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.54%. Given Sunesis Pharmaceuticals’ higher possible upside, analysts clearly believe Sunesis Pharmaceuticals is more favorable than its peers.
Insider & Institutional Ownership
38.4% of Sunesis Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 10.2% of Sunesis Pharmaceuticals shares are owned by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Sunesis Pharmaceuticals has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Sunesis Pharmaceuticals’ peers have a beta of 1.56, indicating that their average stock price is 56% more volatile than the S&P 500.
Sunesis Pharmaceuticals peers beat Sunesis Pharmaceuticals on 8 of the 12 factors compared.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.